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Since 15 years, our research group works on a new thera-
peutic approach of chronic diseases [1,2], we present here
new drug candidates able to fight against GRAM – bacteria
and some multi-resistant ones. These drugs based on the
synthesis of iatrogenic polypeptides on which are linked
endogenous small sized molecules. The different bacterial
strains used in this study were: GRAM – strains: Citrobacter
koseri, Citrobacter diversus, Escherichia coli, Klebsiella pneu-
moniae, Klebsiella oxytoca, Morganella morganii, Proteus
mirabilis, Pseudomonas putida, Pseudomonas aeruginosa, Ser-
ratia marcescens, Alcalescens dispar, and Hafnia alvei; and
antibiotic multi-resistant Gram – strains: Escherichia coli,
Pseudomonas aeruginosa and Alkalescens dispar.
Before testing, we have produced many fatty acid poly-L-
lysine conjugates. Fatty acids and small compounds
linked to PL were: acetic acid (C2)-PL, lactic acid (C3)-PL,
propionic acid (C3)-PL, pyruvic acid (C3)-PL, butyric acid
(C4)-PL, Succinic acid (C4)-PL, glutaric acid (C5)-PL, cap-
roic acid (C6)-PL, caprylic acid (C8)-PL, azelaic acid (C9)-
PL, capric acid (C10)-PL, lauric acid (C12)-PL, myristic acid
(C14)-PL, palmitic acid (C16)-PL, Oleic acid (C18)-PL. Each
conjugate was evaluated on the different bacteria strains.
On the Petri dish test, the densitometric criteria of bacteria
were always a value of 0.5 in the McFarland scale. The
evaluation of the inhibition has been done for each PL-
conjugates tested on each bacterial strain. Thus, the solu-
tions were considered as bactericidal when after incuba-
tion in the optimal conditions no colonies appears to
grown in period of 24 hours or more.
First of all, we have found that: 1) the most active com-
pounds were: C4-PL, C8-PL, C10-PL, C12-PL; 2) the
major part of bacteria strains were sensitive. To increase
the bactericidal effect of fatty acid-PL conjugate, we have
combined different mixtures and found that the best was:
C10-PL-C12 and C4-PL. This mixture was also tested on
antibiotic multi-resistant gram – strains. The strongly bac-
tericidal activity was obtained after: 1) 3 hours for
Escherichia coli; 2) 5 hours for Pseudomonas aeruginosa.
These new drug candidates were effective on GRAM – bac-
teria inhibiting completely their development. The effects
were independent of the cell wall. Our data show: 1) the
importance of the fatty acid when they are linked to PL; 2)
the efficacy of different products (bactericidal activities)
on strains which were in some cases multi-resistant. These
conjugates open new therapeutic perspectives for chronic
diseases in which bacteria are implicated.
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